Lower Death Risk for Vascular Dementia than for Alzheimer’s Disease with Postmenopausal Hormone Therapy Users.

J Clin Endocrinol Metab. 2016 Dec 1:jc20163590. [Epub ahead of print]

Lower Death Risk for Vascular Dementia than for Alzheimer’s Disease with Postmenopausal Hormone Therapy Users.

Author information

  • 11 University of Helsinki and Helsinki University Hospital, Obstetrics and Gynecology, Haartmaninkatu 2, 00029 Helsinki, Finland.
  • 22 Folkhälsan Research Center, Biomedicum, Haartmaninkatu 8, 00029 Helsinki, Finland.
  • 33 EPID Research Oy, Metsänneidonkuja 12, 02130 Espoo, Finland.
  • 44 National Institute for Health and Welfare, Mannerheimintie 166, 00271 Helsinki, Finland and Karolinska Institute, Department of Neurobiology, Care Sciences and Society, Division of Family Medicine, Stockholm, Sweden.

Abstract

CONTEXT:

There are conflicting data on postmenopausal hormone therapy (HT) and the risk of vascular dementia (VD) and Alzheimer’s disease (AD).

OBJECTIVE:

We analyzed the mortality risk attributable to VD or AD in women with a history of HT use. Design, Patients, Interventions and Main Outcome Measures: A total of 489,105 Finnish women using systemic HT in 1994-2009 were identified from the nationwide drug reimbursement register. Of these women, 581 died of VD and 1057 of AD in 1998-2009. The observed deaths in HT users with <5 or ≥5 years of exposure were compared with those having occurred in the age-standardized female population. Furthermore, we compared the VD or AD death risk of women who had started the use of HT at <60 versus ≥60 years of age.

RESULTS:

The risk of death caused by VD was reduced by 37-39% (<5 or ≥5 years of exposure) with the use of any systemic HT, and this reduction was not associated with the duration or type (estradiol-only or estradiol-progestin combination) of HT. The risk of death caused by AD was not reduced with systemic HT <5 years of use, but was slightly reduced (15%) if the HT exposure had exceeded 5 years. The age at systemic HT initiation of <60 versus ≥60 years did not affect the death risk reductions.

CONCLUSION:

Estradiol-based HT use is associated with a reduced risk of death both from VD and AD, but the risk reduction is larger and appears sooner in VD than AD

About Dr Colin Holloway

Gp interested in natural hormone treatment for men and women of all ages

Posted on July 12, 2017, in Uncategorized. Bookmark the permalink. Leave a comment.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: